Study finds superior drug combo for difficult-to-control epilepsy

December 14, 2011

A combination of two common drugs, lamotrigine and valproate, is more effective in treating difficult-to control epilepsy than other anti-epileptic regimens, according to a University of Washington report to be published online this week in Neurology, the journal of the American Academy of Neurology.

More than 3 million Americans have epilepsy, and about one million of these have a difficult-to-treat form.

In a large-scale, of a population of with very difficult-to-control epilepsy, researchers discovered that only the lamotrigine/valproate , out of the 32 studied, significantly decreased seizure frequency in this group.

This specific combination reduced by about half, on average, compared to other regimens. Although it rarely produced complete freedom from seizures, the combination was superior to others in reducing the number of convulsive seizures patients experienced.

Dr. Nicholas P. Poolos, a University of Washington associate professor of neurology who practices at the UW Medicine Regional Epilepsy Center in Seattle, led the project team of pharmacists and a neurobiologist.

Poolos explained that most people with epilepsy have good control of seizures, which means that they have been seizure-free for at least 12 consecutive months. About one third of people with epilepsy are "medically refractory." They continue to have seizures, despite trying several drug combinations prescribed by their physicians.

Physicians have had little evidence to guide them on which drugs or drug combinations, from a multitude of possibilities, might be of most help for patients with difficult-to-treat epilepsy.

This long-standing clinical challenge was the impetus for Poolos and his team to conduct a major study, the first of its size and kind to look retrospectively at patients treated for refractory epilepsy. They went into the project with no about which regimens to test.

"Identifying any anti-epileptic drug regimen with superior efficacy in patients with refractory epilepsy would be a substantial advance," the researchers believed.

What made this study possible was the discovery of 30 years of epilepsy treatment records at two Washington state institutions for the developmentally disabled. At these institutions, the Fircrest Habilitation Center in Shoreline, Wash., and the Rainier Residential Habilitation Center in Buckley, Wash., nursing staff had been recording the occurrence of each convulsive seizure in their patients with epilepsy, along with records of each patient's dosing of anti-epileptic medications.

The researchers determined that out of 32 most frequently used combinations of anti-epileptic drugs, only the and valproate combination had superior efficacy, compared to an aggregate measure of other drug regimens to which the patients had been exposed, as well as head-to-head comparisons with other anti-epileptic drug combinations. The researchers looked at both older and newer generation drugs.

"The study results dispel the dogma that all drug treatments are equally ineffective for this patient population," Poolos said, "and provide evidence for future, prospective drug trials."

The researchers said that their findings reported this week on the superior efficacy of the combination should ideally be confirmed in a prospective study of patients with refractory , preferably from the general population.

The researchers also were surprised to find that while concurrent use of two anti-epileptic drugs was more effective than a single drug alone, three drugs at a time offered no additional benefits. Limiting the combination to two may lessen side effects from taking more kinds of anti-epileptic drugs, without sacrificing efficacy.

Explore further: Non-epileptic seizures may be misdiagnosed longer in veterans

Related Stories

Non-epileptic seizures may be misdiagnosed longer in veterans

September 5, 2011
Psychogenic non-epileptic seizures may go undiagnosed for much longer in veterans compared to civilians, according to a new study published in the September 6, 2011, print issue of Neurology, the medical journal of the American ...

New drug may reduce seizures in epilepsy

April 13, 2011
A new drug called perampanel appears to significantly reduce seizures in people with hard-to-control epilepsy, according to results of the first clinical trial to test the higher 12 mg dose of the drug. The late-breaking ...

Recommended for you

Zebrafish study reveals clues to healing spinal cord injuries

July 25, 2017
Fresh insights into how zebrafish repair their nerve connections could hold clues to new therapies for people with spinal cord injuries.

Brain stimulation may improve cognitive performance in people with schizophrenia

July 24, 2017
Brain stimulation could be used to treat cognitive deficits frequently associated with schizophrenia, according to a new study from King's College London.

New map may lead to drug development for complex brain disorders, researcher says

July 24, 2017
Just as parents are not the root of all their children's problems, a single gene mutation can't be blamed for complex brain disorders like autism, according to a Keck School of Medicine of USC neuroscientist.

Bird songs provide insight into how developing brain forms memories

July 24, 2017
Researchers at the University of Chicago have demonstrated, for the first time, that a key protein complex in the brain is linked to the ability of young animals to learn behavioral patterns from adults.

Research identifies new brain death pathway in Alzheimer's disease

July 24, 2017
Alzheimer's disease tragically ravages the brains, memories and ultimately, personalities of its victims. Now affecting 5 million Americans, Alzheimer's disease is the sixth leading cause of death in the U.S., and a cure ...

Illuminating neural pathways in the living brain

July 24, 2017
Using light alone, scientists from the Max Planck Institute of Neurobiology in Martinsried are now able to reveal pairs or chains of functionally connected neurons under the microscope. The new optogenetic method, named Optobow, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.